Aditya Birla Sun Life Pharma and Healthcare Fund · Direct · Growth
NAV
₹40.9800
as of 17 Nov 2026
Expense Ratio
1.04%
Lumpsum returns (CAGR)
- 1Y
- +18.03%
- 3Y
- +19.91%
- 5Y
- +15.91%
- Since Inception
- +21.13%
SIP returns (XIRR)
- 1Y
- +24.65%
- 3Y
- +16.05%
- 5Y
- +19.38%
- Since Inception
- +19.31%
Performance Comparison
Sectoral allocation
as of 31 Oct 2026- Pharmaceuticals & Biotechnology76.39%
- Healthcare Services21.73%
- Insurance0.71%
- Chemicals & Petrochemicals0.58%
Each sector links to the mutual funds most exposed to it.
Thinking about Aditya Birla Sun Life Pharma and Healthcare Fund · Direct · Growth?
Talk to our AMFI-registered team — free, no pressure. We'll help you see if this fund fits your goals.
Compare with Similar Funds
Fund Details
Available transactions
Portfolio holdings
portfolio shared with Aditya Birla Sun Life Pharma and Healthcare Fund-Regular-Growth
- 1Torrent Pharmaceuticals Ltd.8.83%
- 2Sun Pharmaceutical Industries Ltd.8.35%
- 3Cipla Ltd.7.10%
- 4Apollo Hospitals Enterprise Ltd.6.60%
- 5Sai Life Sciences Ltd.4.54%
- 6Aurobindo Pharma Ltd.4.50%
- 7Ajanta Pharma Ltd.4.17%
- 8Dr. Lal Path Labs Ltd.3.90%
- 9Mankind Pharma Ltd.3.56%
- 10Emcure Pharmaceuticals Ltd.3.06%
Investment objective — in the AMC’s words
The scheme provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India.
About This Fund
Aditya Birla Sun Life Pharma and Healthcare Fund · Direct · Growth is a Sectoral / Thematic mutual fund offered by Aditya Birla Sun Life Mutual Fund. The fund has been operational for over 7 years. It benchmarks its performance against BSE Healthcare. The current expense ratio is 1.04%.
Who Should Invest?
- •Aggressive investors comfortable with significant short-term volatility
- •Investors with a long-term horizon of 7+ years who can ride out market cycles
- •SIP investors who can benefit from rupee cost averaging during market fluctuations